Literature DB >> 20433177

Gaussian processes for classification: QSAR modeling of ADMET and target activity.

Olga Obrezanova1, Matthew D Segall.   

Abstract

In this article, we extend the application of the Gaussian processes technique to classification quantitative structure-activity relationship modeling problems. We explore two approaches, an intrinsic Gaussian processes classification technique and a probit treatment of the Gaussian processes regression method. Here, we describe the basic concepts of the methods and apply these techniques to building category models of absorption, distribution, metabolism, excretion, toxicity and target activity data. We also compare the performance of Gaussian processes for classification to other known computational methods, namely decision trees, random forest, support vector machines, and probit partial least squares. The results indicate that, while no method consistently generates the best model, the Gaussian processes classifier often produces more predictive models than those of the random forest or support vector machines and was rarely significantly outperformed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20433177     DOI: 10.1021/ci900406x

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  9 in total

Review 1.  Computational methods in drug discovery.

Authors:  Gregory Sliwoski; Sandeepkumar Kothiwale; Jens Meiler; Edward W Lowe
Journal:  Pharmacol Rev       Date:  2013-12-31       Impact factor: 25.468

2.  ADMET evaluation in drug discovery. 12. Development of binary classification models for prediction of hERG potassium channel blockage.

Authors:  Sichao Wang; Youyong Li; Junmei Wang; Lei Chen; Liling Zhang; Huidong Yu; Tingjun Hou
Journal:  Mol Pharm       Date:  2012-03-16       Impact factor: 4.939

Review 3.  Advances in the study of drug metabolism - symposium report of the 12th Meeting of the International Society for the Study of Xenobiotics (ISSX).

Authors:  Laura E Russell; Mary Alexandra Schleiff; Eric Gonzalez; Aaron G Bart; Fabio Broccatelli; Jessica H Hartman; W Griffith Humphreys; Volker M Lauschke; Iain Martin; Chukwunonso Nwabufo; Bhagwat Prasad; Emily E Scott; Matthew Segall; Ryan Takahashi; Mitchell E Taub; Jasleen K Sodhi
Journal:  Drug Metab Rev       Date:  2020-05-26       Impact factor: 4.518

4.  A classification study of respiratory Syncytial Virus (RSV) inhibitors by variable selection with random forest.

Authors:  Ming Hao; Yan Li; Yonghua Wang; Shuwei Zhang
Journal:  Int J Mol Sci       Date:  2011-02-21       Impact factor: 5.923

Review 5.  Artificial intelligence to deep learning: machine intelligence approach for drug discovery.

Authors:  Rohan Gupta; Devesh Srivastava; Mehar Sahu; Swati Tiwari; Rashmi K Ambasta; Pravir Kumar
Journal:  Mol Divers       Date:  2021-04-12       Impact factor: 3.364

6.  Proteochemometric modeling in a Bayesian framework.

Authors:  Isidro Cortes-Ciriano; Gerard Jp van Westen; Eelke Bart Lenselink; Daniel S Murrell; Andreas Bender; Thérèse Malliavin
Journal:  J Cheminform       Date:  2014-06-28       Impact factor: 5.514

7.  Mode of Action Analyses of Neferine, a Bisbenzylisoquinoline Alkaloid of Lotus (Nelumbo nucifera) against Multidrug-Resistant Tumor Cells.

Authors:  Onat Kadioglu; Betty Y K Law; Simon W F Mok; Su-Wei Xu; Thomas Efferth; Vincent K W Wong
Journal:  Front Pharmacol       Date:  2017-05-05       Impact factor: 5.810

8.  A novel adaptive ensemble classification framework for ADME prediction.

Authors:  Ming Yang; Jialei Chen; Liwen Xu; Xiufeng Shi; Xin Zhou; Zhijun Xi; Rui An; Xinhong Wang
Journal:  RSC Adv       Date:  2018-03-26       Impact factor: 4.036

9.  Discovery of Novel Hepatitis C Virus NS5B Polymerase Inhibitors by Combining Random Forest, Multiple e-Pharmacophore Modeling and Docking.

Authors:  Yu Wei; Jinlong Li; Jie Qing; Mingjie Huang; Ming Wu; Fenghua Gao; Dongmei Li; Zhangyong Hong; Lingbao Kong; Weiqiang Huang; Jianping Lin
Journal:  PLoS One       Date:  2016-02-04       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.